Mycophenolate mofetil (CellCept)

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

General information

Class/mechanism: Immunosuppressive medication, inhibits inosine monophosphate dehydrogenase (IMPDH). Mycophenolate mofetil is converted in vivo to the active agent mycophenolic acid (MPA), which is a reversible, selective, and non-competitive inhibitor of inosine monophosphate dehydrogenase (IMPDH). MPA results in the inhibition of the de novo synthesis of guanosine, which T and B-cells are dependent upon for proliferation (as opposed to other cell types, which can use salvage pathways). MPA has a cytostatic effect on lymphocytes, suppresses antibody formation by B-cells, and inhibits T and B-cell proliferative response to mitogenic and allospecific stimuli. MPA also inhibits glycosylation of glycoproteins that play a role in intercellular adhesion to endothelial cells, which may suppress localization of leukocytes to areas of inflammation or graft rejection.[1][2][3]
Route: PO, IV
Extravasation: no information

For conciseness and simplicity, currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.[1]

Toxicity management

Disease for which it is used

Patient drug information

History of changes in FDA indication

  • 1995-05-03: Initial FDA approval

History of changes in EMA indication

  • 1996-02-14: Initial authorization

History of changes in PMDA indication

Also known as

  • Brand name: CellCept, Myclausen, Myfenex